CYTK

Cytokinetics, Incorporated

73.96 USD
-0.02 (-0.03%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cytokinetics, Incorporated stock is down -9.66% since 30 days ago. The next earnings date is May 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55% of the previous 19 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
28 Feb 20:15 21 Jun, 2024 80.00 CALL 47 116
28 Feb 20:21 21 Jun, 2024 80.00 CALL 130 116
29 Feb 16:56 21 Jun, 2024 80.00 CALL 169 1346
29 Feb 16:56 21 Jun, 2024 80.00 CALL 25 1346
01 Mar 14:43 21 Jun, 2024 80.00 CALL 39 1584
01 Mar 14:43 21 Jun, 2024 80.00 CALL 124 1584
01 Mar 14:44 21 Jun, 2024 80.00 CALL 209 1584
01 Mar 18:59 17 May, 2024 75.00 PUT 92 428
01 Mar 19:03 17 May, 2024 75.00 PUT 32 428
01 Mar 20:03 08 Mar, 2024 75.00 PUT 264 114

About Cytokinetics, Incorporated

Cytokinetics, Incorporated focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.